Autonomix Medical, Inc. Common Stock Price & Performance (AMIX)

Tivic Health Systems has initiated a 1-for-17 reverse stock split to meet Nasdaq's minimum bid price requirement. Effective March 7, 2025, this action follows a delisting warning in December 2024. While aiming to retain Nasdaq listing, the steep split ratio highlights underlying financial struggles, leaving investors cautious about future performance.1

Autonomix Medical's stock has plummeted to a 52-week low of $2.23, reflecting a 96% drop over the past year. Despite strong liquidity and progress on its ASIC microchip for pancreatic cancer treatment, the company faces significant market challenges. Investors remain wary as the firm works toward clinical trials and FDA approval.23

Autonomix Medical has received a U.S. patent for its catheter-based microchip sensing array. This innovation enhances neural signal detection and offers dual functionality for pain management. Following the announcement, shares rose 10% pre-market, signaling optimism for its potential applications in pancreatic cancer and other conditions.4